GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Nu-Med Plus Inc (OTCPK:NUMD) » Definitions » Operating Income

Nu-Med Plus (Nu-Med Plus) Operating Income : $-0.11 Mil (TTM As of Mar. 2024)


View and export this data going back to 2013. Start your Free Trial

What is Nu-Med Plus Operating Income?

Nu-Med Plus's Operating Income for the three months ended in Mar. 2024 was $-0.02 Mil. Its Operating Income for the trailing twelve months (TTM) ended in Mar. 2024 was $-0.11 Mil.

Operating Margin % is calculated as Operating Income divided by its Revenue. Nu-Med Plus's Operating Income for the three months ended in Mar. 2024 was $-0.02 Mil. Nu-Med Plus's Revenue for the three months ended in Mar. 2024 was $0.00 Mil. Therefore, Nu-Med Plus's Operating Margin % for the quarter that ended in Mar. 2024 was %.

Nu-Med Plus's 5-Year average Growth Rate for Operating Margin % was 0.00% per year.

Operating Income or EBIT is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Nu-Med Plus's annualized ROC % for the quarter that ended in Mar. 2024 was -84.00%. Nu-Med Plus's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2024 was %.


Nu-Med Plus Operating Income Historical Data

The historical data trend for Nu-Med Plus's Operating Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Nu-Med Plus Operating Income Chart

Nu-Med Plus Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Operating Income
Get a 7-Day Free Trial Premium Member Only Premium Member Only -1.02 -2.00 -0.84 -0.18 -0.12

Nu-Med Plus Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Operating Income Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.03 -0.02 -0.02 -0.06 -0.02

Nu-Med Plus Operating Income Calculation

Operating Income, is the profit a company earned through operations. All expenses, including cash expenses such as cost of goods sold (COGS), research & development, wages, and non-cash expenses, such as depreciation, depletion and amortization, have been deducted from the sales.

Operating Income for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.11 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Nu-Med Plus  (OTCPK:NUMD) Operating Income Explanation

1. Operating Income or EBIT is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Nu-Med Plus's annualized ROC % for the quarter that ended in Mar. 2024 is calculated as:

ROC % (Q: Mar. 2024 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Dec. 2023 ) + Invested Capital (Q: Mar. 2024 ))/ count )
=-0.084 * ( 1 - 0% )/( (0.1 + 0.1)/ 2 )
=-0.084/0.1
=-84.00 %

where

Note: The Operating Income data used here is four times the quarterly (Mar. 2024) data.

2. Joel Greenblatt's definition of Return on Capital:

Nu-Med Plus's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2024 is calculated as:

ROC (Joel Greenblatt) %(Q: Mar. 2024 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Dec. 2023  Q: Mar. 2024
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=-0.084/( ( (0 + max(-0.054, 0)) + (0 + max(-0.075, 0)) )/ 2 )
=-0.084/( ( 0 + 0 )/ 2 )
=-0.084/0
= %

where Working Capital is:

Working Capital(Q: Dec. 2023 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0 + 0 + 0.006) - (0.06 + 0 + 0)
=-0.054

Working Capital(Q: Mar. 2024 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0 + 0 + 0.003) - (0.078 + 0 + 0)
=-0.075

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Mar. 2024) EBIT data.

3. Operating Income is also linked to Operating Margin %:

Nu-Med Plus's Operating Margin % for the quarter that ended in Mar. 2024 is calculated as:

Operating Margin %=Operating Income (Q: Mar. 2024 )/Revenue (Q: Mar. 2024 )
=-0.021/0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

4. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Operating Income growth rate using Operating Income per share data.


Be Aware

Compared with a company's EBITDA margin, Operating Margin can be manipulated by adjusting the rate of depreciation, depletion and amortization (DDA).

If a company is facing competition, its Operating Margin may decline. Often the Operating Margin declines well before the company's revenue or even profit decline. Therefore, Operating Margin is a very important indicator of whether the company is facing problems.

For instance, by 2012, Nokia (NOK)'s problems were well known and its stock had lost more than 90% of its market value since 2007. But Nokia's Operating Margin had already been in decline since 2002, although its earnings per share were still rising. Investors who paid attention to Operating Margin would have avoided this huge loss. The same can be said for Research-in-Motion (RIMM).

Therefore, Operating Margin is a very important screening filter for GuruFocus. GuruFocus's Buffett-Munger screener requires that the profit margin is either consistent or expanding. The Model Portfolio of the Buffett-Munger screener has outperformed the market every year since inception in 2009.


Nu-Med Plus Operating Income Related Terms

Thank you for viewing the detailed overview of Nu-Med Plus's Operating Income provided by GuruFocus.com. Please click on the following links to see related term pages.


Nu-Med Plus (Nu-Med Plus) Business Description

Traded in Other Exchanges
N/A
Address
640 Belle Terre Road, Building 2 E Port, Jefferson, NY, USA, 11777
Nu-Med Plus Inc is an medical device company principally engaged in the design, innovation, development, enhancement, and commercialization of beginning, early, and selective later-stage quality medical devices. It focuses on the formulation of Nitric Oxide powder, which is a desktop generator device which delivers inhaled Nitric Oxide to replace expensive pressurized canisters and a mobile rechargeable device to deliver inhaled Nitric Oxide gas to offer solutions to hospitals, health systems and medical community throughout the world.
Executives
William C Hayde director, officer: CEO 76 CLIFF ROAD, BELLE TERRE NY 11777
Wendy P. Smith 10 percent owner P. O. BOX 1374, SALT LAKE CITY UT 84110
Brett J. Earl director, officer: VP of Medical Marketing P.O. BOX 729, MORGAN UT 84050
Mark Edward Christensen officer: CFO, Sec, Treas, Prin Acct Off 455 E. 500 S., SUITE 207, SALT LAKE CITY UT 84111
Thomas A Tait 10 percent owner 514 AMERICAS WAY #5556, BOX ELDER SD 57719
Craig Morrison director, 10 percent owner, officer: Vice President of Technology 975 NORTH TERRACE DRIVE, PROVO UT 84604
William G Moon director, 10 percent owner, officer: Vice President of Operations 1266 SOUTH 1380 WEST, OREM UT 84058
Jeffrey Lynn Robins director, 10 percent owner, officer: CEO 455 EAST 500 SOUTH, SUITE #205, SALT LAKE CITY UT 84111